Home › Compare › NIOVF vs ABBV
NIOVF yields 9389.67% · ABBV yields 3.06%● Live data
📍 NIOVF pulled ahead of the other in Year 1
Combined, NIOVF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NIOVF + ABBV for your $10,000?
Plato Gold Corp., a junior exploration company, engages in the exploration, evaluation, and development of gold and rare mineral properties in Canada. It holds 100% interest in the Good Hope Niobium project comprising 254 claims, which include 227 single cell mining claims and 27 boundary cell mining claims covering an area of approximately 5,146 hectares located in northwest of Marathon, Ontario. The company also has an option to acquire a 100% interest in the Pic River Platinum Group Metals project comprising 111 single cell mining claims covering an area of approximately 2,247 hectares located in Marathon, Ontario; and the Lolita project, which includes three adjoining concessions located in Southern Argentina. In addition, it holds interest in the Timmins Gold project that comprise of four properties, including the Guibord, Harker, and Holloway properties that include 4 mining leases; and the Marriott property comprising 98 claims located in east of Timmins. The company is based in Toronto, Canada.
Full NIOVF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.